Importantly, the combination of palbociclib with enzalutamide, a selective AR inhibitor, abrogates palbociclib resistance in BC cell lines [148], suggesting that AR can be a new possible target in BC patients resistant to CDK4/6i. This evidence concerns the gene CDK4 and breast cancer.